{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:44:24Z","timestamp":1792640664285,"version":"4.5.0"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>Risankizumab, a monoclonal interleukin 23p19 antibody, is a treatment for ulcerative colitis. This post hoc analysis reports the efficacy and safety of risankizumab for ulcerative colitis in patients in East Asia from the global phase 3 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the 12\u2010week, phase 2b\/3 induction study (NCT03398148), adults with moderately to severely active ulcerative colitis were randomized 2:1 to intravenous risankizumab 1200\u2009mg or placebo at Weeks 0, 4, and 8. Patients with clinical response to 12\u2009weeks of intravenous risankizumab induction therapy were randomized 1:1:1 to subcutaneous risankizumab 180\u2009mg, risankizumab 360\u2009mg, or placebo (risankizumab withdrawal) every 8\u2009weeks in the 52\u2010week phase 3 maintenance study (NCT03398135). This post hoc analysis evaluated data from patients in China, Japan, South Korea, and Taiwan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 256 and 130 East Asian patients in the induction and maintenance studies, respectively, were analyzed. Clinical remission per Adapted Mayo score was achieved at higher rates with risankizumab vs. placebo at induction Week 12 (risankizumab 1200\u2009mg, 21.7%; placebo, 5.8%) and maintenance Week 52 (risankizumab 180\u2009mg, 36.9%; risankizumab 360\u2009mg, 58.0%; placebo [withdrawal], 26.7%). Clinical, endoscopic, and histologic outcomes were achieved at higher rates with risankizumab vs. placebo induction and maintenance therapy. Treatment\u2010emergent adverse event rates were similar between treatment groups in induction and maintenance studies with no new safety signals identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Risankizumab improved disease outcomes among patients with moderately to severely active ulcerative colitis in East Asian countries, with a safety profile consistent with the global study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgh.70800","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:35:49Z","timestamp":1792640149000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Risankizumab Among Patients With Ulcerative Colitis in East Asia: A Post Hoc Analysis of Two Randomized Clinical Trials"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-1801","authenticated-orcid":false,"given":"Ken","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, IBD Centre Tsujinaka Hospital Kashiwanoha  Kashiwa Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital Zhejiang University School of Medicine  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Ozeki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-7896","authenticated-orcid":false,"given":"Sang\u2010Bum","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine The Catholic University of Korea  Daejeon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-6487","authenticated-orcid":false,"given":"Jen\u2010Wei","family":"Chou","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine China Medical University Hospital  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuja","family":"Mallick","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Matsuda","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre A.","family":"Morisset","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Kalabic","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG  Ludwigshafen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronilda","family":"D'Cunha","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Zhang","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Rachel","family":"Duan","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh\u2010Ying","family":"Yeh","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Kyorin University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"10401","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative Colitis","volume":"402","author":"Berre C. L.","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ueg2.12350","article-title":"The Epidemiology of Inflammatory Bowel Disease in Asia and Asian Immigrants to Western Countries","volume":"10","author":"Aniwan S.","year":"2022","journal-title":"United European Gastroenterology Journal"},{"issue":"13","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.cgh.2023.08.013","article-title":"Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population\u2010Based Study","volume":"21","author":"Xu L.","year":"2023","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"10114","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population\u2010Based Studies","volume":"390","author":"Ng S. C.","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17474124.2021.1840976","article-title":"Epidemiology, Burden of Disease, and Unmet Needs in the Treatment of Ulcerative Colitis in Asia","volume":"15","author":"Wei S. C.","year":"2021","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114081","article-title":"The Treatment of Inflammatory Bowel Disease With Monoclonal Antibodies in Asia","volume":"157","author":"Chen Y.","year":"2023","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"3","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jgh.14872","article-title":"The Epidemiology of Inflammatory Bowel Disease: East Meets West","volume":"35","author":"Mak W. Y.","year":"2020","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41588-023-01384-0","article-title":"Genetic Architecture of the Inflammatory Bowel Diseases Across East Asian and European Ancestries","volume":"55","author":"Liu Z.","year":"2023","journal-title":"Nature Genetics"},{"key":"e_1_2_11_10_1","volume-title":"Skyrizi (risankizumab) [Product Monograph]","author":"AbbVie Corporation","year":"2026"},{"key":"e_1_2_11_11_1","volume-title":"Rinvoq (upadacitinib) [Prescribing Information]","author":"AbbVie Inc","year":"2025"},{"key":"e_1_2_11_12_1","volume-title":"Rinvoq (upadacitinib) [Summary of Product Characteristics]","author":"European Medicines Agency","year":"2025"},{"issue":"11","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for Ulcerative Colitis","volume":"332","author":"Louis E.","year":"2024","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf005","article-title":"Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies","volume":"19","author":"Panaccione R.","year":"2025","journal-title":"Journal of Crohn's and Colitis"},{"issue":"3","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clinthera.2021.01.009","article-title":"Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto\u2010Injector for Subcutaneous Injection","volume":"43","author":"Lon H. K.","year":"2021","journal-title":"Clinical Therapeutics"},{"key":"e_1_2_11_16_1","first-page":"65","article-title":"Significance Levels From Repeated p\u2010Values With Multiply\u2010Imputed Data","volume":"1","author":"Li K. H.","year":"1991","journal-title":"Statistica Sinica"},{"issue":"5","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s12325-020-01615-4","article-title":"Real\u2010World Prescription Pattern and Healthcare Cost Among Patients With Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis","volume":"38","author":"Miyazaki C.","year":"2021","journal-title":"Advances in Therapy"},{"issue":"9","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/ueg2.12634","article-title":"Natural Course of Ulcerative Colitis in China: Differences From the West?","volume":"12","author":"Wan J.","year":"2024","journal-title":"United European Gastroenterology Journal"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgh.70800","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:35:52Z","timestamp":1792640152000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.70800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":17,"alternative-id":["10.1111\/jgh.70800"],"URL":"https:\/\/doi.org\/10.1111\/jgh.70800","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"2025-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jgh.70800"}}